EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial)
Primary Purpose
Atrial Fibrillation
Status
Not yet recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Atrial fibrillation catheter ablation group
Medical therapy group
Sponsored by
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- Patients aged between 20 and 80 years of age who have appropriate indication for catheter ablation for AF
- AF patients with left atrium diameter <55 mm
- Antiarrhythmic drug-resistant AF
- Anticoagulation eligible patients
Exclusion Criteria:
- AF associated with severe cardiac malformation or structural heart disease
- Patients undergoing treatment for cognitive disorders, emotional disorders, and anxiety disorders
- Patients with severe renal dysfunction or difficulty in CT imaging using contrast media
- Patients with a previous history of AF ablation or other open heart surgery
- Patients with active internal bleeding
- Anticoagulant therapy not eligible patients
- Valvular AF (mitral valve stenosis>grade 2, mechanical valve, mitral valve reconstruction)
- Significant comorbidities
- Patients with an expected survival period of less than 1 year
- Drug or alcohol addiction patients
- Among eligible persons, those who cannot read the consent form (illiteracy, foreigners, etc.)
- Patients judged to be unsuitable for participation in clinical research based on the judgment of other researchers
Sites / Locations
- Yonsei University Health System, Severance Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Atrial fibrillation catheter ablation group
Medical therapy group
Arm Description
catheter ablation
standard treatment include anti-arrhythmic drug
Outcomes
Primary Outcome Measures
Changes in cognitive function, depression, and anxiety scale after catheter ablation or drug treatment after 1 year of randomization
Compasison of scale change using the Moca questionnaire.
Changes in depression scale after catheter ablation or drug treatment after 1 year of randomization
Compasison of scale change using the CES-D questionnaire.
Changes in anxiety scale after catheter ablation or drug treatment after 1 year of randomization
Compasison of scale change using the GAD-7 questionnaire.
Secondary Outcome Measures
Differences according to AF type
Differences in adverse effects of ablation vs. medications
Differences in MACE, Death, and Readmission rate
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04942171
Brief Title
EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial)
Official Title
EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy; Randomized Clinical Trial (EMOTICON Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 2021 (Anticipated)
Primary Completion Date
February 23, 2026 (Anticipated)
Study Completion Date
February 23, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
"Atrial fibrillation (AF) is an arrhythmic disease that increases especially in the elderly, increasing the risk of ischemic stroke by 5 times and is a major cause of dementia and cognitive impairment.
Cognitive dysfunction accompanying AF occurs regardless of the presence or absence of stroke, and AF itself is known to affect cognitive function.
However, since cognitive dysfunction is also affected by various accompanying chronic diseases, whether the cognitive dysfunction accompanying AF is due to subclinical ischemic stroke, cerebral hypoperfusion due to reduced cardiac output, inflammatory reaction or platelet dysfunction are unclear.
Recently, this research team reported an improvement in cognitive function with active sinus rhythm therapy such as AF catheter ablation. Nevertheless, it has not yet been proven whether such active and invasive AF treatment affects the improvement of cognitive function or depression by a randomized clinical trial.
In this prospective randomized clinical comparative study, the investigators will compare the AF catheter ablation group and drug therapy group in terms of cognitive function tests and depression psychological tests at baseline and a year after treatment. Our hypothesis is that AF catheter ablation is superior to drug therapy to improve cognitive function and depressive mood.
Detailed Description
Study design
Prospective randomization (catheter ablation group vs. drug treatment group) (Python program is used, the random number module is imported using the import random syntax, and the random number table of the two groups is prepared and used)
Target number of targets 320 (160 for each group)
Cardiac rhythm follow-up: 2012 ACC/AHA/ESC guidelines (baseline, 3 months, every 6 months after Holter, Electrocardiogram when symptoms are present)
Anticoagulant therapy follows 2014 ACC/AHA/ESC guidelines.
Evaluation of MOCA score (cognitive function), CES-D score (depression), and GAD-7 score (anxiety) at baseline and a year after treatment, respectively.
Evaluation of all adverse events occurring in each group, hospitalization rate, major cardiovascular attack, and mortality rate comparison
Progress and rhythm/ ECG follow-up
Implemented in accordance with 2012 ACC/AHA/HRS guidelines for AF management
Baseline MOCA, CES-D, and GAD-7 score evaluation
Outpatient follow-up observation 1 to 2 weeks after the start of the procedure or medication
Follow-up observation at intervals of 2 months, 6 months, and then every 6 months after starting the procedure or medication
If the patient complains of arrhythmia symptoms, conduct an electrocardiogram at any time, and follow the rhythm with a Holter or event recorder.
Follow-up MOCA, CES-D, and GAD-7 score evaluation
Follow-up observation
All patients are scheduled to visit the outpatient clinic every 6 months after 1~2 weeks, 2 months, 6 months, and even if they have symptoms in the middle, they will be treated as an outpatient at any time.
An ECG is administered at every outpatient visit. A 24-hour Holter or event recorder was administered for 1 year at intervals of 2, 6, and 6 months after the procedure (2012 Heart Rhythm Society/EHRA/European Cardiac Arrhythmia Society Expert Consensus Statement guidelines).
If atrial fibrillation or atrial tachycardia lasting more than 30 seconds is observed on a standard electrocardiogram, event electrocardiogram, or Holter, it is evaluated as recurrence. Recurrence within 3 months after the procedure is classified as early recurrence, and recurrence after 3 months is classified as clinical recurrence.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Atrial fibrillation catheter ablation group
Arm Type
Experimental
Arm Description
catheter ablation
Arm Title
Medical therapy group
Arm Type
Active Comparator
Arm Description
standard treatment include anti-arrhythmic drug
Intervention Type
Procedure
Intervention Name(s)
Atrial fibrillation catheter ablation group
Intervention Description
Pulmonary vein isolation
Additional treatment for lesions caused by non-pulmonary veins
Esophageal temperature monitoring to prevent damage to the esophagus
Evaluation of procedure time and radiofrequency ablation time
Evaluation of complications after the procedure
Rhythm follow-up after the procedure is conducted in accordance with the above study design.
Conduct a survey on cognitive function and emotion before and 12 months after the procedure
Intervention Type
Drug
Intervention Name(s)
Medical therapy group
Intervention Description
Use of beta-blockers or calcium channel blockers for pulse rate control
Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.
If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.
To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.
Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure
Primary Outcome Measure Information:
Title
Changes in cognitive function, depression, and anxiety scale after catheter ablation or drug treatment after 1 year of randomization
Description
Compasison of scale change using the Moca questionnaire.
Time Frame
1 year
Title
Changes in depression scale after catheter ablation or drug treatment after 1 year of randomization
Description
Compasison of scale change using the CES-D questionnaire.
Time Frame
1 year
Title
Changes in anxiety scale after catheter ablation or drug treatment after 1 year of randomization
Description
Compasison of scale change using the GAD-7 questionnaire.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Differences according to AF type
Time Frame
1year
Title
Differences in adverse effects of ablation vs. medications
Time Frame
1year
Title
Differences in MACE, Death, and Readmission rate
Time Frame
1year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged between 20 and 80 years of age who have appropriate indication for catheter ablation for AF
AF patients with left atrium diameter <55 mm
Antiarrhythmic drug-resistant AF
Anticoagulation eligible patients
Exclusion Criteria:
AF associated with severe cardiac malformation or structural heart disease
Patients undergoing treatment for cognitive disorders, emotional disorders, and anxiety disorders
Patients with severe renal dysfunction or difficulty in CT imaging using contrast media
Patients with a previous history of AF ablation or other open heart surgery
Patients with active internal bleeding
Anticoagulant therapy not eligible patients
Valvular AF (mitral valve stenosis>grade 2, mechanical valve, mitral valve reconstruction)
Significant comorbidities
Patients with an expected survival period of less than 1 year
Drug or alcohol addiction patients
Among eligible persons, those who cannot read the consent form (illiteracy, foreigners, etc.)
Patients judged to be unsuitable for participation in clinical research based on the judgment of other researchers
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hui-Nam Pak
Phone
82-2-2228-8459
Email
hnpak@yuhs.ac
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hui-Nam Pak
Organizational Affiliation
Yonsei University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yonsei University Health System, Severance Hospital
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hui-Nam Pak
Phone
82-2-2228-8459
Email
hnpak@yuhs.ac
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial)
We'll reach out to this number within 24 hrs